Sponsor or institution
Clinical trials and research at ORIC Pharmaceuticals
As of November 12, 2026, Find a Trial lists 4 clinical trials run by ORIC Pharmaceuticals that are recruiting, at sites in 11 countries (most in United States (4), Australia (3), Canada (2)). By phase: Phase 1 (2), Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 11Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure | Phase 3 | Glendale, California and 14 other locations | Recruiting | Jul 23, 2026 |
| Combining ORIC-114 with Amivantamab for NSCLC with EGFR Exon 20 Insertion Mutations | Phase 1 | New York, New York and 3 other locations | Recruiting | Feb 10, 2025 |
| Testing ORIC-944 for metastatic prostate cancer treatment | Phase 1 | Colorado Springs, Colorado and 26 other locations | Recruiting | Jun 10, 2022 |
| Treatment with ORIC-114 for advanced solid tumors with EGFR or HER2 alterations | Phase 1/2 | Duarte, California and 41 other locations | Recruiting | Apr 7, 2022 |
All recruiting trials (4)
-
Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure
This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.
-
Combining ORIC-114 with Amivantamab for NSCLC with EGFR Exon 20 Insertion Mutations
This study is testing a new combination of two drugs, ORIC-114 and amivantamab, to see if they can help people with advanced lung cancer that has a specific genetic mutation.
-
Testing ORIC-944 for metastatic prostate cancer treatment
This study is testing a new drug called ORIC-944 to see if it can safely help people with metastatic prostate cancer, both on its own and when combined with other treatments.
-
Treatment with ORIC-114 for advanced solid tumors with EGFR or HER2 alterations
This study is testing a new drug called ORIC-114 to see if it can help people with advanced solid tumors that have specific genetic changes related to EGFR or HER2.
Quick answers
How many clinical trials run by ORIC Pharmaceuticals are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in United States (4 trials), Australia (3 trials), Canada (2 trials), Spain (2 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.